Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Foretinib
Synonyms
Therapy Description

Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, KDR (VEGFR2), as well as ROS1 and NTRK fusions, which may result in decreased tumor angiogenesis and growth (PMID: 19808973, PMID: 26372962, PMID: 29463555, PMID: 30501104).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Foretinib GSK1363089G|XL880|EXEL-2880 MET Inhibitor 59 ROS1 Inhibitor 20 TrkA Receptor Inhibitor 8 TYRO3 Inhibitor 8 VEGFR2 Inhibitor 37 Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, KDR (VEGFR2), as well as ROS1 and NTRK fusions, which may result in decreased tumor angiogenesis and growth (PMID: 19808973, PMID: 26372962, PMID: 29463555, PMID: 30501104).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 D835V hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 D835V (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 F691L hematologic cancer sensitive Foretinib Preclinical - Cell line xenograft Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 F691L, and inhibited tumor cell growth in a cell line xenograft model (PMID: 38231480). 38231480
FLT3 exon 14 ins hematologic cancer sensitive Foretinib Preclinical - Cell line xenograft Actionable In a preclinical study, Foretinib (GSK1363089) inhibited growth of cultured cells expressing FLT3-ITD mutations, and led to decreased tumor burden and improved survival in a cell line xenograft model (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 D835V hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 D835V (PMID: 38231480). 38231480
FLT3 exon 14 ins acute myeloid leukemia sensitive Foretinib Preclinical - Pdx & cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cell lines and primary patient-derived acute myeloid leukemia cells harboring FLT3-ITD in culture, led to decreased tumor burden and improved survival in a cell line and a patient-derived xenograft (PDX) model (PMID: 38231480). 38231480
FLT3 D835E acute myeloid leukemia sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3 D835E in culture (PMID: 38231480). 38231480
FLT3 exon 14 ins NRAS G12C acute myeloid leukemia decreased response Foretinib Preclinical - Cell culture Actionable In a preclinical study, acute myeloid leukemia cells harboring FLT3-ITD and expressing NRAS G12C were less sensitive to Foretinib (GSK1363089) in culture (PMID: 38231480). 38231480
FLT3 N676K hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 N676K (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 Y842C hematologic cancer sensitive Foretinib Preclinical - Cell line xenograft Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 Y842C and improved survival in a cell line xenograft model (PMID: 38231480). 38231480
FLT3 D835Y hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 D835Y (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3-ITD with FLT3 D835Y in culture (PMID: 38231480). 38231480
FLT3 Y842C hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 Y842C (PMID: 38231480). 38231480
FLT3 D835V acute myeloid leukemia sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3 D835V in culture (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 D835V acute myeloid leukemia sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of primary patient-derived acute myeloid leukemia blasts harboring FLT3-ITD with FLT3 D835V in culture (PMID: 38231480). 38231480
FLT3 exon 14 ins FLT3 D835Y hematologic cancer sensitive Foretinib Preclinical - Cell line xenograft Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 D835Y, and led to improved survival in a cell line xenograft model (PMID: 38231480). 38231480

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST